Equity Details
Price & Market Data
Price: $4.18
Daily Change: +$0.38 / 9.09%
Daily Range: $3.93 - $4.35
Market Cap: $156,796,656
Daily Volume: 4,057
Performance Metrics
1 Week: 6.49%
1 Month: -5.53%
3 Months: -12.71%
6 Months: -0.12%
1 Year: 5.13%
YTD: -6.61%
About Molecular Partners AG (MOLN)
Comprehensive market data and analysis for Molecular Partners AG (MOLN). Current price: 4.18, daily change: +$0.38 / 9.09%. Market cap: 156,796,656. View detailed YTD, 1-week, and 1-month performance.
Company Details
Employees: 149
Sector: Health technology
Industry: Biotechnology
Country: Switzerland
Details
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
